The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug. Local authorities and relevant stakeholders are closely monitoring the situation as fresh developments unfold on the ground. Officials noted that further verified updates and administrative measures will be shared following a detailed review.